Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.66 |
| ▸ | HTR2B | P41595 | 5/20 | 0.66 |
| ▸ | SCD | O00767 | 9/20 | 0.53 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16279347 | 0.98 | HTR2C (0.64) | HTR2CHTR2BSCDNOS1NOS3 | |
| SCHEMBL2463260 | 0.88 | HTR2C (0.66) | HTR2CHTR2BSCDNOS1NOS2 | |
| SCHEMBL5871363 | 0.82 | HTR2C (0.50) | HTR2CHTR2BNOS1NOS3NOS2 | |
| SCHEMBL4995439 | 0.82 | HTR2C (0.63) | HTR2CHTR2BSCDNOS1NOS3 | |
| SCHEMBL7172358 | 0.79 | HTR2C (1.00) | HTR2CHTR2B | |
| SCHEMBL5871641 | 0.78 | HTR2C (0.65) | HTR2CHTR2BSCDNOS1NOS3 | |
| SCHEMBL2709111 | 0.78 | HTR2C (0.77) | HTR2CHTR2BSCDNOS1NOS3 | |
| SCHEMBL16229892 | 0.77 | NOS1 (0.53) | HTR2CHTR2BNOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL3947175 | 0.76 | HTR2C (0.75) | HTR2CHTR2BSCDNOS1NOS3 | |
| SCHEMBL5871631 | 0.76 | ADRA2A (0.46) | HTR2CHTR2BNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238658-B2 | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-19 | — | — | US | disclosed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | disclosed |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-20140364393-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | US | disclosed |
| WO-2013085957-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013085957-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013085954-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364393-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, FASN | HTR2C 1942/4885HTR2B 1893/4885SCD 1/4885 |
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | HTR2C 222/4885HTR2B 91/4885SCD 2882/4885 |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, PLIN1 | HTR2C 1690/4885HTR2B 1971/4885SCD 1/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | HTR2C 107/4885HTR2B 45/4885SCD 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.